title: Idelalisib for the treatment of chronic lymphocytic leukemia.
abstract: Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those with progressive or clinically advanced disease will require treatment. Cytotoxic drugs, such as the alkylating agents, purine nucleoside antagonists, and immunotherapeutic agents, have been the mainstay of chemotherapeutic treatment in CLL. However, given the lack of therapeutic specificity, these medications (especially older ones) have limited tolerability due to side effects. In this paper, we will discuss the data on the use of phosphatidylinositol 3 kinase inhibitor Idelalisib in the management of patients with chronic lymphocytic leukemia. The preclinical and clinical data thus far demonstrate that Idelalisib produces a dramatic and durable response in patients with chronic lymphocytic leukemia and without causing significant toxicity. Moving forward, the ongoing clinical trials will help address the various questions currently being raised regarding the long-term application and safety of Idelalisib. With greater clinical experience following more widespread use of Idelalisib, we will be able to determine the optimal combination therapies in treatment-naïve and relapsed/refractory patients, resulting in more individualized therapeutic strategies for patients with chronic lymphocytic leukemia.
authors.affiliation: Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, USA.
authors.forename: Maliha
authors.initials: M
authors.lastname: Khan
authors.affiliation: Dow University of Health Sciences, Karachi 74200, Pakistan.
authors.forename: Areeba
authors.identifier: 0000-0002-6902-2254
authors.initials: A
authors.lastname: Saif
authors.affiliation: Department of Internal Medicine, Presence Resurrection Medical Center, 7435 West Talcott Avenue Chicago, IL 60631, USA.
authors.forename: Steven
authors.identifier: 0000-0003-3789-0230
authors.initials: S
authors.lastname: Sandler
authors.affiliation: Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, USA.
authors.forename: Aibek E
authors.identifier: 0000-0003-1604-1053
authors.initials: AE
authors.lastname: Mirrakhimov
references.citation: Adv Exp Med Biol. 2013;792:259-91
references.pmid: 24014301
references.citation: Front Oncol. 2013 Mar 01;3:40
references.pmid: 23459844
references.citation: J Immunol. 2004 Aug 15;173(4):2236-40
references.pmid: 15294934
references.citation: Semin Cancer Biol. 2013 Dec;23(6):410-21
references.pmid: 24060900
references.citation: Leuk Lymphoma. 2004 Dec;45(12):2365-72
references.pmid: 15621749
references.citation: Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
references.pmid: 20379207
references.citation: Blood. 2008 Feb 1;111(3):1497-503
references.pmid: 18025150
references.citation: J Clin Oncol. 2012 Aug 10;30(23):2820-2
references.pmid: 22778323
references.citation: Blood. 2011 Jan 13;117(2):591-4
references.pmid: 20959606
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):267-72
references.pmid: 22187458
references.citation: J Leukoc Biol. 2013 Jan;93(1):161-70
references.pmid: 23136257
references.citation: J Biol Chem. 2001 Aug 10;276(32):30011-7
references.pmid: 11406619
references.citation: Blood. 2006 Jan 15;107(2):642-50
references.pmid: 16179367
references.citation: J Intern Med. 2008 Dec;264(6):549-62
references.pmid: 19017179
references.citation: Nature. 2012 Sep 13;489(7415):309-12
references.pmid: 22885698
references.citation: J Exp Med. 2001 Dec 3;194(11):1625-38
references.pmid: 11733577
references.citation: J Exp Med. 2006 Oct 30;203(11):2551-62
references.pmid: 17060474
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):273-8
references.pmid: 22187460
references.citation: Biochem J. 2012 Mar 15;442(3):465-81
references.pmid: 22364281
references.citation: Leukemia. 2014 May;28(5):1060-70
references.pmid: 24170027
references.citation: Blood. 2011 Apr 21;117(16):4323-7
references.pmid: 21378270
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:481-8
references.pmid: 21239840
references.citation: Curr Hematol Malig Rep. 2013 Mar;8(1):22-7
references.pmid: 23114654
references.citation: Eur J Immunol. 2008 Dec;38(12):3543-8
references.pmid: 19016531
references.citation: Blood. 2012 Aug 9;120(6):1175-84
references.pmid: 22715122
references.citation: Int J Cancer. 2013 Jul;133(1):247-52
references.pmid: 23238639
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Hematology Am Soc Hematol Educ Program. 2013;2013:158-67
references.pmid: 24319177
references.citation: Br J Haematol. 2013 Oct;163(1):72-80
references.pmid: 23889282
references.citation: Oncotarget. 2014 Feb 28;5(4):908-15
references.pmid: 24659719
references.citation: N Engl J Med. 2014 Mar 13;370(11):997-1007
references.pmid: 24450857
references.citation: Clin Cancer Res. 2014 Feb 1;20(3):548-56
references.pmid: 24323900
references.citation: Leukemia. 2013 Oct;27(10):2094-6
references.pmid: 23900138
references.citation: Mediterr J Hematol Infect Dis. 2013 Nov 04;5(1):e2013068
references.pmid: 24363883
references.citation: Blood. 2010 Sep 23;116(12):2078-88
references.pmid: 20522708
references.citation: Mediterr J Hematol Infect Dis. 2012;4(1):e2012067
references.pmid: 23170196
references.citation: Front Immunol. 2012 Aug 09;3:224
references.pmid: 22908014